1. Home
  2. MAIA vs CIGL Comparison

MAIA vs CIGL Comparison

Compare MAIA & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • CIGL
  • Stock Information
  • Founded
  • MAIA 2018
  • CIGL 1997
  • Country
  • MAIA United States
  • CIGL Singapore
  • Employees
  • MAIA N/A
  • CIGL N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • CIGL Diversified Commercial Services
  • Sector
  • MAIA Health Care
  • CIGL Consumer Discretionary
  • Exchange
  • MAIA Nasdaq
  • CIGL Nasdaq
  • Market Cap
  • MAIA 56.3M
  • CIGL 46.7M
  • IPO Year
  • MAIA 2022
  • CIGL 2025
  • Fundamental
  • Price
  • MAIA $1.70
  • CIGL $3.18
  • Analyst Decision
  • MAIA
  • CIGL
  • Analyst Count
  • MAIA 0
  • CIGL 0
  • Target Price
  • MAIA N/A
  • CIGL N/A
  • AVG Volume (30 Days)
  • MAIA 464.6K
  • CIGL 7.9M
  • Earning Date
  • MAIA 11-11-2025
  • CIGL 01-01-0001
  • Dividend Yield
  • MAIA N/A
  • CIGL N/A
  • EPS Growth
  • MAIA N/A
  • CIGL N/A
  • EPS
  • MAIA N/A
  • CIGL N/A
  • Revenue
  • MAIA N/A
  • CIGL $10,490,668.00
  • Revenue This Year
  • MAIA N/A
  • CIGL N/A
  • Revenue Next Year
  • MAIA N/A
  • CIGL N/A
  • P/E Ratio
  • MAIA N/A
  • CIGL N/A
  • Revenue Growth
  • MAIA N/A
  • CIGL N/A
  • 52 Week Low
  • MAIA $1.40
  • CIGL $1.40
  • 52 Week High
  • MAIA $3.48
  • CIGL $31.06
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 58.76
  • CIGL N/A
  • Support Level
  • MAIA $1.54
  • CIGL N/A
  • Resistance Level
  • MAIA $1.78
  • CIGL N/A
  • Average True Range (ATR)
  • MAIA 0.09
  • CIGL 0.00
  • MACD
  • MAIA 0.02
  • CIGL 0.00
  • Stochastic Oscillator
  • MAIA 75.00
  • CIGL 0.00

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About CIGL Concorde International Group Ltd Class A Ordinary Shares

Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.

Share on Social Networks: